175 related articles for article (PubMed ID: 30619040)
1. Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients.
Castellazzi M; Ligi D; Contaldi E; Quartana D; Fonderico M; Borgatti L; Bellini T; Trentini A; Granieri E; Fainardi E; Mannello F; Pugliatti M
Front Neurol; 2018; 9():1080. PubMed ID: 30619040
[No Abstract] [Full Text] [Related]
2. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases.
Liuzzi GM; Mastroianni CM; Santacroce MP; Fanelli M; D'Agostino C; Vullo V; Riccio P
J Neurovirol; 2000 Apr; 6(2):156-63. PubMed ID: 10822329
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
[TBL] [Abstract][Full Text] [Related]
5. Chemokines and matrix metalloproteinases in cerebrospinal fluid of patients with central nervous system complications caused by varicella-zoster virus.
Lind L; Eriksson K; Grahn A
J Neuroinflammation; 2019 Feb; 16(1):42. PubMed ID: 30777092
[TBL] [Abstract][Full Text] [Related]
6. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
Uchida T; Mori M; Uzawa A; Masuda H; Muto M; Ohtani R; Kuwabara S
Mult Scler; 2017 Jul; 23(8):1072-1084. PubMed ID: 27682231
[TBL] [Abstract][Full Text] [Related]
7. Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis.
Puthenparampil M; Marin A; Zanotelli G; Mauceri VA; De Napoli F; Gaggiola M; Miscioscia A; Ponzano M; Bovis F; Perini P; Rinaldi F; Molon B; Gallo P
Mult Scler Relat Disord; 2024 Feb; 82():105403. PubMed ID: 38184910
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019.
Mohammadhosayni M; Sadat Mohammadi F; Ezzatifar F; Mahdavi Gorabi A; Khosrojerdi A; Aslani S; Hemmatzadeh M; Yazdani S; Arabi M; Marofi F; Jadidi-Niaragh F; Shomali N; Mohammadi H
Int Immunopharmacol; 2021 Nov; 100():108076. PubMed ID: 34450402
[TBL] [Abstract][Full Text] [Related]
9. An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis.
Boziki M; Grigoriadis N
Med Chem; 2018 Feb; 14(2):155-169. PubMed ID: 28875862
[TBL] [Abstract][Full Text] [Related]
10. Increased matrix metalloproteinases in cerebrospinal fluids of patients with major depressive disorder and schizophrenia.
Omori W; Hattori K; Kajitani N; Tsuchioka MO; Boku S; Kunugi H; Okamoto Y; Takebayashi M
Int J Neuropsychopharmacol; 2020 Jul; 23(11):713-20. PubMed ID: 32671384
[TBL] [Abstract][Full Text] [Related]
11. Metalloproteinases and their tissue inhibitors in multiple sclerosis.
Ozenci V; Rinaldi L; Teleshova N; Matusevicius D; Kivisäkk P; Kouwenhoven M; Link H
J Autoimmun; 1999 Jun; 12(4):297-303. PubMed ID: 10330301
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.
Candelario-Jalil E; Thompson J; Taheri S; Grossetete M; Adair JC; Edmonds E; Prestopnik J; Wills J; Rosenberg GA
Stroke; 2011 May; 42(5):1345-50. PubMed ID: 21454822
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury.
Minta K; Brinkmalm G; Al Nimer F; Thelin EP; Piehl F; Tullberg M; Jeppsson A; Portelius E; Zetterberg H; Blennow K; Andreasson U
Sci Rep; 2020 Oct; 10(1):18075. PubMed ID: 33093584
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica.
Mandler RN; Dencoff JD; Midani F; Ford CC; Ahmed W; Rosenberg GA
Brain; 2001 Mar; 124(Pt 3):493-8. PubMed ID: 11222449
[TBL] [Abstract][Full Text] [Related]
16. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution.
Beseler C; Vollmer T; Graner M; Yu X
PLoS One; 2017; 12(10):e0186842. PubMed ID: 29059249
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease.
Hamzaoui K; Maître B; Hamzaoui A
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S52-7. PubMed ID: 19796534
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
19. Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients.
Trentini A; Castellazzi M; Cervellati C; Manfrinato MC; Tamborino C; Hanau S; Volta CA; Baldi E; Kostic V; Drulovic J; Granieri E; Dallocchio F; Bellini T; Dujmovic I; Fainardi E
Dis Markers; 2016; 2016():3672353. PubMed ID: 27555667
[TBL] [Abstract][Full Text] [Related]
20. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.
Jarius S; König FB; Metz I; Ruprecht K; Paul F; Brück W; Wildemann B
J Neuroinflammation; 2017 Aug; 14(1):171. PubMed ID: 28851393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
